(0.27%) 5 113.65 points
(0.14%) 38 294 points
(0.36%) 15 986 points
(-1.45%) $82.63
(3.48%) $1.990
(0.09%) $2 349.20
(-0.01%) $27.53
(3.28%) $952.30
(-0.07%) $0.934
(-0.15%) $11.01
(-0.34%) $0.798
(1.74%) $93.47
@ $11.29
Išleistas: 13 vas. 2024 @ 22:33
Grąža: -10.36%
Ankstesnis signalas: vas. 13 - 16:30
Ankstesnis signalas:
Grąža: 2.98 %
Live Chart Being Loaded With Signals
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States...
Stats | |
---|---|
Šios dienos apimtis | 44 791.00 |
Vidutinė apimtis | 430 561 |
Rinkos kapitalizacija | 1.04B |
EPS | $0 ( 2024-03-19 ) |
Kita pelno data | ( $-0.740 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.91 |
ATR14 | $0.0230 (0.23%) |
Tūris Koreliacija
Immatics N.V. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
RMRM | 0.966 |
RXT | 0.929 |
SWAV | 0.925 |
UCBI | 0.922 |
NFE | 0.918 |
CCRN | 0.917 |
NVTSW | 0.916 |
GBCI | 0.915 |
FIBK | 0.914 |
THTX | 0.914 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
MLCO | -0.927 |
EZGO | -0.926 |
RXDX | -0.925 |
FWONK | -0.922 |
BRAC | -0.92 |
LUNA | -0.918 |
HWCC | -0.917 |
BKNG | -0.917 |
MLVF | -0.916 |
MOMO | -0.915 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Immatics N.V. Koreliacija - Valiuta/Žaliavos
Immatics N.V. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $54.00M |
Bruto pelnas: | $-64.67M (-119.76 %) |
EPS: | $-1.200 |
FY | 2023 |
Pajamos: | $54.00M |
Bruto pelnas: | $-64.67M (-119.76 %) |
EPS: | $-1.200 |
FY | 2022 |
Pajamos: | $172.83M |
Bruto pelnas: | $66.05M (38.22 %) |
EPS: | $0.550 |
Financial Reports:
No articles found.
Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.